Positron Corp (OTC: POSC) is a medical imaging company that designs, develops, and markets PET-CT systems optimized for cardiovascular applications, specifically cardiac myocardial perfusion imaging. Revenue comes from equipment sales, rentals, lease-to-own arrangements, and associated service and support contracts. The company targets hospitals, outpatient imaging centers, and physician practices seeking to upgrade from legacy SPECT systems to PET-CT technology. For the year ended December 31, 2025, Positron reported a net loss of $10,603,392 ($0.34 per share), compared to a net loss of $2,379,092 ($0.09 per share) for the year ended December 31, 2024, with an accumulated deficit of $144,937,079 as of December 31, 2025. The company's auditors have issued a going-concern opinion, noting recurring losses and negative operating cash flows since inception. Positron sells directly to end-users through a field sales force and supports customers with physician training, billing and reimbursement assistance, clinical over-read services, and 24/7 technical support.

Revenue model

Transactional equipment sales, rental contracts, and lease-to-own programs for PET-CT imaging systems, supplemented by service contracts covering maintenance, software updates, and clinical support services. Revenue has fluctuated significantly year to year, per the FY2025 10-K filed 2026-03-31.

Products and services

PET-CT imaging systems designed for cardiac myocardial perfusion imaging; cardiac-focused imaging software with tools for therapy monitoring, coronary visualization, motion correction, and protocol development; integrated clinical and technical support services including physician and technologist training, billing and prior-authorization assistance, clinical over-read support, and 24/7 technical service.

Customers and end markets

Hospitals, outpatient imaging centers, and physician practices performing nuclear cardiology procedures in the United States. End market is nuclear cardiology, with demand driven by the clinical transition from SPECT to PET-CT imaging for myocardial perfusion imaging. The company estimates approximately 3,000 PET and PET-CT systems were installed in the United States as of 2024, with SPECT systems representing a significantly larger installed base and a long-term replacement opportunity.

Value-chain role

Manufacturer and direct distributor of molecular imaging hardware and software. Positron sells and distributes directly to end-users through a geographically deployed sales force and provides post-sale support through internal clinical and technical personnel, field service engineers, and external clinical consultants.

Geographic exposure

United States, based on filing disclosures referencing U.S. installed base data and U.S. healthcare provider customer types. International geographic breakdown not disclosed in the excerpts reviewed.

Source: SEC 10-K, filed 2026-03-31

Industry: Electromedical & Electrotherapeutic Apparatus